FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

By sjmartinez • January 8, 2025

Spira A, Cho BC, Felip E, Garon EB, Goto K, Johnson M, Leighl N, Passaro A, Planchard D, Popat S, Yang JC, Lu X, Jiang Y, Huang J, Lam M, Kowanetz M, Wang S, Le J, Hsu JY, Zhou CC. FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004). Lung Cancer. 2024 Dec 28;199:108066. doi: 10.1016/j.lungcan.2024.108066. Epub ahead of print. PMID: 39764938.

Tags: advanced, EGFR, EGFR-TKI, Ex20ins, Exon 20 insertions, Firmonertinib, Furmonertinib, Hematology/Oncology, metastatic, Publications

Glucarpidase for Treatment of High-Dose Methotrexate Toxicity

Gupta S, Kaunfer SA, Chen KL, Dias JA, Vijayan A, Rajasekaran A, Prosek J, Truong HL, Wood A, Bassil C, Renaghan AD, Shah CV, Zhang[...]

Warm Autoimmune Hemolytic Anemia as a Rare Presentation of Pre-fibrotic Primary Myelofibrosis

Lai SY, Lo AE, Wu P. Warm Autoimmune Hemolytic Anemia as a Rare Presentation of Pre-fibrotic Primary Myelofibrosis. Cureus. 2024 Dec 5;16(12):e75155. doi: 10.7759/cureus.75155. PMID:[...]

Case report: High-grade serous tubo-ovarian carcinoma with FGFR2::IQCG fusion and insights into targetability

Sono R, Konecny GE, Zhang L. Case report: High-grade serous tubo-ovarian carcinoma with FGFR2::IQCG fusion and insights into targetability. Front Oncol. 2024 Dec 20;14:1514471. doi: 10.3389/fonc.2024.1514471. PMID:[...]